NewslettersCell Therapy NewsUncategorizedEngineering CAR-T Cells to Activate Small-Molecule Drugs In SituBy Justin.choi - January 4, 2022017To overcome these problems, scientists developed a novel class of CAR-T cells engineered to express an enzyme that activated a systemically administered small-molecule prodrug in situ at a tumor site.[Nature Chemical Biology] 6445212 AAAAAAAA items 1 apa 0 default asc 1 170190 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/AbstractFull ArticlePress Release